Literature DB >> 24951765

Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension.

Marlene Rabinovitch1, Christophe Guignabert2, Marc Humbert2, Mark R Nicolls2.   

Abstract

This review summarizes an expanding body of knowledge indicating that failure to resolve inflammation and altered immune processes underlie the development of pulmonary arterial hypertension. The chemokines and cytokines implicated in pulmonary arterial hypertension that could form a biomarker platform are discussed. Pre-clinical studies that provide the basis for dysregulated immunity in animal models of the disease are reviewed. In addition, we present therapies that target inflammatory/immune mechanisms that are currently enrolling patients, and discuss others in development. We show how genetic and metabolic abnormalities are inextricably linked to dysregulated immunity and adverse remodeling in the pulmonary arteries.
© 2014 American Heart Association, Inc.

Entities:  

Keywords:  hypertension, pulmonary; leukotriene B4

Mesh：

Substances：

Year:  2014        PMID： 24951765      PMCID： PMC4097142          DOI： 10.1161/CIRCRESAHA.113.301141

Source DB:  PubMed          Journal:  Circ Res        ISSN： 0009-7330            Impact factor:   17.367


  141 in total

1.  Early macrophage recruitment and alternative activation are critical for the later development of hypoxia-induced pulmonary hypertension.

Authors:  Eleni Vergadi; Mun Seog Chang; Changjin Lee; Olin D Liang; Xianlan Liu; Angeles Fernandez-Gonzalez; S Alex Mitsialis; Stella Kourembanas
Journal:  Circulation       Date:  2011-04-25       Impact factor: 29.690

Review 2.  Macrophage plasticity and polarization: in vivo veritas.

Authors:  Antonio Sica; Alberto Mantovani
Journal:  J Clin Invest       Date:  2012-03-01       Impact factor: 14.808

Review 3.  Th1 and Th17 cells: adversaries and collaborators.

Authors:  Jesse M Damsker; Anna M Hansen; Rachel R Caspi
Journal:  Ann N Y Acad Sci       Date:  2010-01       Impact factor: 5.691

4.  Exogenous leukocyte and endogenous elastases can mediate mitogenic activity in pulmonary artery smooth muscle cells by release of extracellular-matrix bound basic fibroblast growth factor.

Authors:  K Thompson; M Rabinovitch
Journal:  J Cell Physiol       Date:  1996-03       Impact factor: 6.384

5.  Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor.

Authors:  Carl Atkinson; Susan Stewart; Paul D Upton; Rajiv Machado; Jennifer R Thomson; Richard C Trembath; Nicholas W Morrell
Journal:  Circulation       Date:  2002-04-09       Impact factor: 29.690

6.  Dexamethasone attenuates development of monocrotaline-induced pulmonary arterial hypertension.

Authors:  Wei Wang; Yu-Lin Wang; Xiao-Ying Chen; Yu-Tang Li; Wei Hao; You-Peng Jin; Bo Han
Journal:  Mol Biol Rep       Date:  2011-03-23       Impact factor: 2.316

7.  Monocrotaline-induced pulmonary arterial hypertension is attenuated by TNF-α antagonists via the suppression of TNF-α expression and NF-κB pathway in rats.

Authors:  Qiang Wang; Xiang-rong Zuo; Yan-yan Wang; Wei-ping Xie; Hong Wang; Miaojia Zhang
Journal:  Vascul Pharmacol       Date:  2012-07-28       Impact factor: 5.773

Review 8.  Ectopic lymphoid tissues and local immunity.

Authors:  Damian M Carragher; Javier Rangel-Moreno; Troy D Randall
Journal:  Semin Immunol       Date:  2008-02-19       Impact factor: 11.130

9.  Resistin-like molecule-beta in scleroderma-associated pulmonary hypertension.

Authors:  Daniel J Angelini; Qingning Su; Kazuyo Yamaji-Kegan; Chunling Fan; Xingwu Teng; Paul M Hassoun; Stephen C Yang; Hunter C Champion; Rubin M Tuder; Roger A Johns
Journal:  Am J Respir Cell Mol Biol       Date:  2009-02-27       Impact factor: 6.914

10.  Krüppel-like factor 5 contributes to pulmonary artery smooth muscle proliferation and resistance to apoptosis in human pulmonary arterial hypertension.

Authors:  Audrey Courboulin; Véronique L Tremblay; Marjorie Barrier; Jolyane Meloche; Maria Helena Jacob; Mathilde Chapolard; Malik Bisserier; Roxane Paulin; Caroline Lambert; Steeve Provencher; Sébastien Bonnet
Journal:  Respir Res       Date:  2011-09-27
View more
  304 in total

1.  Transglutaminase 2 in pulmonary and cardiac tissue remodeling in experimental pulmonary hypertension.

Authors:  Krishna C Penumatsa; Deniz Toksoz; Rod R Warburton; Mousa Kharnaf; Ioana R Preston; Navin K Kapur; Chaitan Khosla; Nicholas S Hill; Barry L Fanburg
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-08-03       Impact factor: 5.464

Review 2.  Update in Pulmonary Vascular Diseases 2014.

Authors:  Elena A Goncharova; Mark T Gladwin; Steven M Kawut
Journal:  Am J Respir Crit Care Med       Date:  2015-09-01       Impact factor: 21.405

Review 3.  Discovery of a murine model of clinical PAH: Mission impossible?

Authors:  Zhiyu Dai; You-Yang Zhao
Journal:  Trends Cardiovasc Med       Date:  2016-12-15       Impact factor: 6.677

4.  Whole-Blood RNA Profiles Associated with Pulmonary Arterial Hypertension and Clinical Outcome.

Authors:  Christopher J Rhodes; Pablo Otero-Núñez; John Wharton; Emilia M Swietlik; Sokratis Kariotis; Lars Harbaum; Mark J Dunning; Jason M Elinoff; Niamh Errington; A A Roger Thompson; James Iremonger; J Gerry Coghlan; Paul A Corris; Luke S Howard; David G Kiely; Colin Church; Joanna Pepke-Zaba; Mark Toshner; Stephen J Wort; Ankit A Desai; Marc Humbert; William C Nichols; Laura Southgate; David-Alexandre Trégouët; Richard C Trembath; Inga Prokopenko; Stefan Gräf; Nicholas W Morrell; Dennis Wang; Allan Lawrie; Martin R Wilkins
Journal:  Am J Respir Crit Care Med       Date:  2020-08-15       Impact factor: 21.405

5.  Toll-like Receptor 3 Is a Therapeutic Target for Pulmonary Hypertension.

Authors:  Daniela Farkas; A A Roger Thompson; Aneel R Bhagwani; Schuyler Hultman; Hyun Ji; Naveen Kotha; Grant Farr; Nadine D Arnold; Adam Braithwaite; Helen Casbolt; Jennifer E Cole; Ian Sabroe; Claudia Monaco; Carlyne D Cool; Elena A Goncharova; Allan Lawrie; Laszlo Farkas
Journal:  Am J Respir Crit Care Med       Date:  2019-01-15       Impact factor: 21.405

6.  Cytokines, Chemokines, and Inflammation in Pulmonary Arterial Hypertension.

Authors:  Shuxin Liang; Ankit A Desai; Stephen M Black; Haiyang Tang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

7.  PPARγ Regulates Mitochondrial Structure and Function and Human Pulmonary Artery Smooth Muscle Cell Proliferation.

Authors:  Samantha M Yeligar; Bum-Yong Kang; Kaiser M Bijli; Jennifer M Kleinhenz; Tamara C Murphy; Gloria Torres; Alejandra San Martin; Roy L Sutliff; C Michael Hart
Journal:  Am J Respir Cell Mol Biol       Date:  2018-05       Impact factor: 6.914

Review 8.  The molecular rationale for therapeutic targeting of glutamine metabolism in pulmonary hypertension.

Authors:  Thomas Bertero; Dror Perk; Stephen Y Chan
Journal:  Expert Opin Ther Targets       Date:  2019-05-11       Impact factor: 6.902

9.  Dominant Role for Regulatory T Cells in Protecting Females Against Pulmonary Hypertension.

Authors:  Rasa Tamosiuniene; Olga Manouvakhova; Paul Mesange; Toshie Saito; Jin Qian; Mrinmoy Sanyal; Yu-Chun Lin; Linh P Nguyen; Amir Luria; Allen B Tu; Joshua M Sante; Marlene Rabinovitch; Desmond J Fitzgerald; Brian B Graham; Aida Habtezion; Norbert F Voelkel; Laure Aurelian; Mark R Nicolls
Journal:  Circ Res       Date:  2018-03-15       Impact factor: 17.367

Review 10.  Pulmonary arterial hypertension: pathogenesis and clinical management.

Authors:  Thenappan Thenappan; Mark L Ormiston; John J Ryan; Stephen L Archer
Journal:  BMJ       Date:  2018-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.